The National Institutes of Health has provided $50,000 in funding to CTSI to fund clinical trials for the treatment of drug abuse for the study: Repositioning Ivermectin for the Treatment of Alcohol Use Disorders/First in Human Studies.

USC’s CTSI (Southern California Clinical and Translational Science Institute) laboratory recently found that ivermectin (IVM), an FDA approved drug for other indications, significantly reduced ethanol intake in both male and female mice following acute IVM administration.

This pilot project marks the start of the translation from animal studies to humans for the use of IVM as a therapy for alcohol use disorders (AUDs). The results from this pilot project should provide the first clinical and preclinical evidence that IVM can be repurposed as a novel therapeutic agent to treat AUDs.

The multidisciplinary team effort is led by Co-Principal Investigators Dr. Daryl Davies, Dr. Stan Louie and Dr. Kathleen Rodgers with Co-Investigator Dr. Eunjoo Pacifici.